Funds and ETFs Swedish Orphan Biovitrum AB

SOBI

SE0000872095

Name	Weight	AuM	1st Jan change	Investor Rating
XACT SVERIGE UCITS ETF - SEK	1.15%	233 M€	+5.60%
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	0.90%	5 M€	+5.20%
FIRST TRUST INTERNATIONAL IPO ETF - USD	0.69%	148 M€	+4.52%	-
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.25%	1,120 M€	-1.90%
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF (CAD-HEDGED) - CAD	0.09%	5 M€	+10.09%	-
ISHARES EDGE MSCI MULTIFACTOR EAFE INDEX ETF - CAD	0.09%	14 M€	+5.66%	-
AMUNDI MSCI EUROPE EX UK UCITS ETF (C) - EUR	0.05%	6 M€	-.--%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.03%	6 M€	-.--%
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.02%	7 M€	+0.11%	-
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.02%	10 M€	-3.35%	-
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.01%	205 M€	-.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.01%	273 M€	+11.25%
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.01%	284 M€	-.--%
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.00%	389 M€	+5.17%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	34 M€	+5.42%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	17 M€	+1.06%	-
AMUNDI INDEX MSCI WORLD UCITS ETF - EUR	0.00%	1,166 M€	+0.26%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.00%	607 M€	+0.05%	-
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.00%	34 M€	+1.04%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.00%	302 M€	+3.05%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.00%	39 M€	+3.32%	-
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD	0.00%	237 M€	-1.30%	-

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Ratings for Swedish Orphan Biovitrum AB

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

259.4 SEK

Average target price

314.1 SEK

Spread / Average Target

+21.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SWEDISH ORPHAN BIOVITRUM AB	-3.67%	8.07B
CSL LIMITED	-5.99%	84.46B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.85B
BIOGEN INC.	-26.37%	27.69B
UCB	+50.19%	24.28B
BIOMARIN PHARMACEUTICAL INC.	-6.59%	17.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-32.37%	13.67B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.45%	11.79B
INCYTE CORPORATION	-15.88%	11.86B
INTRA-CELLULAR THERAPIES, INC.	+0.53%	7.51B

Biopharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:45:55 2024-04-19 am EDT			5-day change	1st Jan Change
255.3 ^SEK	-1.58%		+1.74%	-3.67%

Mar. 14	Certain Shares of Swedish Orphan Biovitrum AB are subject to a Lock-Up Agreement Ending on 14-MAR-2024.	CI
Feb. 13	Sobi to Expand in South Korea via Rare Disease JV with Handok	MT